Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families by Filippini, Sandra et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
Multiplex SNaPshot for detection of BRCA1/2 common mutations in 
Spanish and Spanish related breast/ovarian cancer families
Sandra Filippini1, Ana Blanco2, Ana Fernández-Marmiesse2, Vanesa Álvarez-
Iglesias1, Clara Ruíz-Ponte2, Ángel Carracedo1,2 and Ana Vega*2
Address: 1Unidade de Xenética, Instituto de Medicina Legal & Grupo de Medicina Xenómica, Facultad de Medicina, Santiago de Compostela, 
Galicia, Spain and 2Unidad de Medicina Molecular, Fundación Pública Galega de Medicina Xenómica_SERGAS, Hospital Clínico de Santiago de 
Compostela, Galicia, Spain
Email: Sandra Filippini - sandraefilip@yahoo.com.ar; Ana Blanco - anablancop@hotmail.com; Ana Fernández-
Marmiesse - ana.fernandez.marmiesse@sergas.es; Vanesa Álvarez-Iglesias - vaneiml@usc.es; Clara Ruíz-Ponte - crponte@usc.es; 
Ángel Carracedo - apimlang@usc.es; Ana Vega* - apimlapv@usc.es
* Corresponding author    
Abstract
Background: It is estimated that 5–10% of all breast cancer are hereditary and attributable to
mutations in the highly penetrance susceptibility genes BRCA1 and BRCA2. The genetic analysis of
these genes is complex and expensive essentially because their length. Nevertheless, the presence
of recurrent and founder mutations allows a pre-screening for the identification of the most
frequent mutations found in each geographical region. In Spain, five mutations in BRCA1 and other
five in BRCA2 account for approximately 50% of the mutations detected in Spanish families.
Methods: We have developed a novel PCR multiplex SNaPshot reaction that targets all ten
recurrent and founder mutations identified in BRCA1 and BRCA2 in Spain to date.
Results:  The SNaPshot reaction was performed on samples previously analyzed by direct
sequencing and all mutations were concordant. This strategy permits the analysis of approximately
50% of all mutations observed to be responsible for breast/ovarian cancer in Spanish families using
a single reaction per patient sample.
Conclusion: The SNaPshot assay developed is sensitive, rapid, with minimum cost per sample and
additionally can be automated for high-throughput genotyping. The SNaPshot assay outlined here
is not only useful for analysis of Spanish breast/ovarian cancer families, but also e.g. for populations
with Spanish ancestry, such as those in Latin America.
Background
Germline mutations in BRCA1  (OMIM 113705) and
BRCA2 (OMIM 600185) account for familial clustering in
the majority of families with both breast and ovarian cancer
and in approximately one-half of families with site-specific
breast cancer [1,2]. BRCA1 and BRCA2 are both large genes
containing 5,592 and 11,385 nucleotides spread over
~100,000 bases of genomic DNA each. There are more than
1,000 BRCA mutations reported to the Breast Cancer Infor-
mation Core (BIC) database [3]; many of them are unique
but there are also numerous examples of recurrent and
founder mutations. Founder mutations have been reported
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in genetic isolate populations such as Ashkenazi Jewish
[4,5], Icelandic [6], Finnish [7], Dutch [8,9] and French
Canadian [10], as well as in Slavic countries, including
Poland [11].
In Spain, a compilation of BRCA test results from different
laboratories shows that five mutations in the BRCA1 gene
(c.187-188delAG [p.Q23fs], c.330A > G, [p.64-71del],
c.5236G > A [p.G1706A], c.5242C > A [p.A1708E], c.589-
590delCT [p.S157X]; numbered GeneBank U14680)
account for 46.6 % of BRCA1 mutations and four in BRCA2
(c.3036-3039delACAA [p.K936fs], c.6857-6858delAA
[p.E2210fs], c.9254-9258del5 [p.Y3009fs], c.9538-
3539delAA [p.K3104fs]; numbered GenBank U43746)
account for 56.6 % of the BRCA2 mutations [12]. Moreo-
ver, an additional founder mutation in the Spanish popu-
lation, located in BRCA2  has recently been observed:
c.5374-5377delTATG [p.Y1716fs] (Comunicated by
Infante M, et al. at the XXIII Congreso Nacional de Genética
Humana, Valladolid, Spain, 2006).
Automated sequencing using standardized procedures rep-
resents the "gold standard" system of analysis (comple-
mented by an assay that can detect copy number changes as
well). However this procedure is time-consuming and
expensive. The identification of fully characterized, recur-
rent mutations could reduce the time and cost of the anal-
ysis. Thus, for instance, Revillion et al. [13] developed a
multiplex single-nucleotide primer extension analysis to
simultaneous detects 36% of French mutations and 32 %
of international ones.
In the present work we describe a rapid, sensitive and low
cost assay based on a multiplexed single nucleotide primer
extension reaction using SNaPshot dye labeled terminators
and capillary electrophoresis to allow rapid detection of
approximately 50% of the mutations detected in BRCA1
and BRCA2 in Spanish families.
Methods
Samples and Extraction method
The 48 DNA patient samples included in this study were
sent to our laboratory for BRCA1 and BRCA2 diagnosis.
Written informed consent was obtained from each patient.
Twenty-four of the 48 DNA samples carried one of the ten
recurring germline mutations in the BRCA1  and BRCA2
genes identified in Spain (BRCA1: c.187-188delAG, c.330A
> G, c.5236G > A, c.5242C > A, c.589-590delCT; numbered
GeneBank U14680; BRCA2: c.3036-3039delACAA, c.5374-
5377delTATG, c.6857-6858delAA, c.9254-9258del5,
c.9538-3539delAA numbered GeneBank U43746). In the
remaining 24 samples, no BRCA1/2  mutations were
present. DNA was extracted from peripheral blood leuco-
cytes by standard procedures.
SNaPshot multiplex primer design
The primers for PCR amplification and SNaPshot extension
reactions (Tables 1 and 2) were both designed to have an
annealing temperature around 60°C using Primer3 soft-
ware [14]. To test for possible repetitive sequences, primers
were aligned with the NCBI sequence databases using
BLAST [15]. AutoDimer Software [16] was used to test for
potential hairpin structures and primer-dimer problems.
Primer synthesis was performed by Sigma-Genosys Ltd.
(Pampisford, Cambridgeshire, UK). All minisequencing
primers were purified by HPLC to remove incomplete
primer synthesis products. Co-amplification in the same
amplicon was used to detect c.5236 G > C and c.589-
590delCT closely positioned in exon 18 of BRCA1. The PCR
product sizes ranged from 151 bp to 250 bp.
The extension primer was designed to anneal immediately
adjacent to the nucleotide at the mutation site, on either
the sense or anti-sense DNA strand, for the detection of
BRCA1 c.5242C > A mutation we used anti-sense primer.
The primer orientation allowed a multiplexed SNaPshot
reaction encompassing all the loci to be detected in the
absence of intra- and inter-primer complementarities.
PCR multiplex amplification
The PCR multiplex co-amplified 9 fragments for the 10
BRCA1/BRCA2 mutations, with sizes ranging from 174 to
250 bp with a single amplicon encompassing the two exon
18 mutations: c.5242 G > A, and c.589-590delCT of BRCA1
gene. Amplification was performed using 5 ng of DNA tem-
plate, 2 × PCR master mix from QIAGEN Multiplex PCR kit
(Qiagen Hilden Germany), 10 × amplification primer mix
(2 μM each primer with final concentration of 0.2 μM, opti-
mal for most primer-template systems). Cycling was carried
out using a 9700 thermocycler (Applied Biosystems, Foster
City, CA, USA). Following a 95°C initial activation step for
HotStar Taq DNA polymerase of 15 minutes, a total of 35
cycles were made using the following conditions: 94°C
denaturation for 30 seconds, primer annealing at 60°C for
90 seconds, followed by 15 minutes of final extension at
72°C and a 4°C holding step. PCR quality and yield were
checked using an Agilent 2100 Expert Bioanalyzer DNA
500/DNA 1000 (Agilent Technologies Inc. Santa Clara, CA
USA).
Minisequencing SNaPshot reaction
After amplification, PCR products required purification to
remove primers and un-incorporated dNTPs. This post-
PCR purification was performed as follows: 1 μl of PCR
product was incubated with 0.5 μl of ExoSapIT (Amershan
Pharmacia Biotech) for 15 min at 37°C followed by 15 min
at 80°C for enzyme inactivation. The minisequencing reac-
tion was performed using the SNaPshot™ kit in a 9700 ther-
mocycler with 2 μl of SNaPshot ready reaction mix, 0.2 μM
of extension primer for each mutation and 1.5 μl of puri-BMC Medical Genetics 2007, 8:40 http://www.biomedcentral.com/1471-2350/8/40
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fied PCR products in a 5 μl total volume. Extension used 25
cycles of denaturation at 96°C for 10 seconds, annealing at
50°C for 5 seconds and extension at 60°C for 30 seconds.
Detection of extension products is based on four different
fluorochromes to assay each base and controlled extension
primer sizes (the length of a primer regulated using differ-
ent sized non-homologous Poly-dGACT tails at the 5' end).
Final extension product sizes ranged between 30 and 72 bp
(see Table 2). After the minisequencing reaction, a post-
extension treatment to remove the 50-phosphoryl group of
the ddNTPs helps to prevent unincorporated terminators
from comigrating with the extended primers and produc-
ing high background signal. For this a 10 μl final volume
was treated with 1 μl of SAP (Amersham Biosciences) for 60
min at 37°C, followed by 15 min at 80°C for enzyme inac-
tivation.
Electroforetic SNaPshot conditions
The minisequencing products (1.5 μl) were mixed with 10
μl of HiDi™ formamide and 0.5 μl of GeneScan-120 LIZ
size standard (Applied Biosystems) and denatured at 95°C
for 5 minutes. The fluorescently labeled fragments were
resolved by capillary electrophoresis on an ABI PRISM
3730 × l Genetic Analyzer (Applied Biosystems). Minise-
quencing products were injected electrokinetically for 10
seconds at 15 kV and electrophorezed for 20 min at 15 kV
and 9 mA at 60°C (default module) in a 36 cm length cap-
illary using POP-7™ polymer with the laser set at a constant
power of 9.9 mW. The resulting data was analyzed with
GeneMapper™ 3.7 Software (Applied Biosystems).
Results
The SNaPshot reaction was performed on samples previ-
ously analyzed by direct sequencing and all mutations were
concordant. Mutations are usually present in the hetero-
zygous state yielding two peaks, one with the expected size
and color and a "mutant" peak with a different color
according to the base incorporated (Fig. 1).
Table 2: Extension primer sequences
Mutation Extension Primer Size bp Change
BRCA1 c.187-188delAG F gactcattaatgctatgcagaaaatcttag 30 A/T
BRCA1 c.5236 G > C F gacttgaacggacactgaaatattttctag 30 G/C
BRCA1 c.330 A > G F gactgatgtcctttatgtaagaatgatataaccaaa 36 A/G
BRCA2 c.5374-5377delTATG F gactgactgactaatactgcagattatgtaggaaattatttg 42 T/A
BRCA1 c.589-590delCT F gactgactgactgactgactgactaaaccagtctcagtgtccaactct 48 C/A
BRCA2 c.3036-3039delACAA F gacgactgactgactgactgactgactggttttatatggagacacaggtgataa 54 A/G
BRCA1 c.5242C > A R acgactgactgactgactgactgactgactgactgactgctaactacccattttcctccc 60 T/G
BRCA2 c.9254-9258del5 F gacgactgactgactgactgactgactgactgttaacagaaggaaagagatacagaattt 60 A/C
BRCA2 c.6857-6858delAA F gacgactgactgactgactgactgactgactgactgactctgatgttcctgtgaaaacaaatatag 66 A/G
BRCA2 c.9538-9539delAA F gagactgactgactgactgactgactgactgactgactgactgactacgaatgttacaatttactggcaata 72 A/G
* Poly(dGACT) tail
Table 1: PCR primer sequences (5'→3')
Mutation (Predicted effect) PCR primers Size bp Exon
BRCA1 c.187-188delAG (p.Q23fs) F ttcgcgttgaagaagtacaaaa
R ttccctagtatgtaaggtcaattctg
151 2
BRCA1 c.330 A > G (p.64-71del) F ggctcttaagggcagttgtg
R cctactgtggttgcttccaa
235 5
BRCA1 c.589-590delCT (p.S157X) F ctcttcaggaggaaaagcaca
R cctgagacccttacccaattc
186 8
BRCA1 c.5236 G > C (p.G1706A)




BRCA2 c.3036-3039delACAA (p.K936fs) F ttcatgaaacagacttgacttgtg
R ttcaaggagatgtccgatttt
208 11
BRCA2 c.5374-5377delTATG (p.Y1716fs) F tggcttagagaaggaatatttgatg
R ctggctcaataccagaatcaag
250 11
BRCA2 c.6857-6858delAA (p.E2210fs) F tgggaaaagaacaggcttca
R gaatgtgtggcatgacttgg
217 11
BRCA2 c.9254-9258del5 (p.Y3009fs) F tcttccattgcatctttctca
R ggtttgtaccggtagttgttga
209 23
BRCA2 c.9538-9539delAA (p.K3104fs) F gagtttcctttcttgcatcttaaa
R gcctgatttggattctggtc
221 25BMC Medical Genetics 2007, 8:40 http://www.biomedcentral.com/1471-2350/8/40
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The electrophoretic mobility of the extension products
depends not only on their lengths, but also on the neigh-
boring nucleotide sequences and on the fluorescent dye
used in the reaction.
Therefore, as expected, the detected size determined by the
automated sequencer and the real size of certain products
were slightly different. It can be tentatively said that to
ensure correct differentiation of the extended primer,
amplicons should differ by at least six nucleotides in
length. Some fragments display stronger fluorescent signal
than others in the electropherogram (even after colour
compensation with the appropriate matrix) due to varia-
tion in minisequencing chemistry. Therefore, mutations are
detected by the automated sequencer at different peak
heights depending on the terminator and dye label. In gen-
eral, guanine labeled with dR100 produces a higher signal
than the other ddNTPs. However, this fact does not unduly
affect the readability of the electropherogram [see also [17]
No false positive results were observed in control samples
without mutations, demonstrating the reliability of the
procedure and repetitive assays proved the reproducibility
of the method.
Discussion
The genetic analysis of BRCA1 and BRCA2 is complex and
expensive essentially because their length. Nevertheless, the
presence of recurrent and founder mutations allows a pre-
screening for the identification of the most frequent muta-
tions found in each geographical region. This is the case of
the single BRCA2 mutation found in the Icelandic popula-
tion (c.999del5), and the 3 founder Ashkenazi Jews muta-
tions that comprise the genetic test targeted to this
population. In contrast to isolated populations the number
of mutations that need to be included in the pre-screening
process in Spanish population is substantially higher: ten
recurrent and founder mutations represent approximately
50 % of the identified familial mutations, and are good
candidates to be included in the pre-screening [12, and
communication of Infante M, et al. at the XXIII Congreso
Nacional de Genética Humana, Spain]. Based on this high-
frequency-mutation group, we have developed a SNaPshot
reaction to analyze all ten mutations in a single assay. This
strategy has numerous advantages. Firstly, a single tube
reaction is used for each patient that implies the reduction
in term of number of steps and handling. Secondly, high-
throughput genotyping is possible as the process can be
automated, and the assay is carried out in 96 wells plates.
In addition, the interpretation of the peak patterns is very
simple and the method is sensitive [see other forensic
applications in 18 and 19] and low cost. Lastly, the design
is highly flexible: (i) more mutations can be added to the
multiplex and (ii) SNaPshot can detect point mutations but
also indels, as in our design (some point mutations: c.330A
> G or c.5236G > A, and some indels: c.187-188delAG or
c.3036-3039delACAA).
The SNaPshot design we propose here represents an
advance in the genetic diagnosis of BRCA1  and  BRCA2
Spanish families, since permits the identification of the
46.6 % of BRCA1 and more than 56.6 % of the BRCA2 fam-
ilies in few hours. Moreover it is not only useful for Spanish
patients, but also for those populations with Spanish ances-
try such as those from Latin American countries. Many fam-
ilies from Latin America can trace their European ancestry
to the period of Spanish colonization, and, in the last cen-
tury, to migratory movements from diverse regions of
Spain. An example of this is the occurrence of two Spanish
mutations c.330A > G in BRCA1 and c.6857-6858delAA in
BRCA2 in populations with Spanish ancestry: the former
was found in Latin/South American/Caribbean families
with Galician ancestors [20,21], and the later mutation was
described in one Chilean family with Catalan origins [12].
The utility of our SNaPshot design in Latin American pop-
ulation also applies to recent admixture populations. Thus,
for instance, the study of Torres et al. [22] shows that three
mutations account for almost 80% of deleterious muta-
tions identified in a Hispanic American cohort from
Colombia. Two of these three mutations are frequent in
Spanish population and included in our SNaPshot multi-
plex design we present here, supporting the utility of our
design for the initial screening of Latino American breast
cancer families. Five of the nine different mutations
observed in Chile [23] are in the Top 20 Mutation Fre-
quency of the BIC database [3]. This suggest that a modified
SNaPshot considering these Top 20 mutation (some
already included in our SNaPshot design) could yield good
results for screening in Chile as in other recently admixture
populations.
Conclusion
In summary, here we propose a fast, flexible and cost-effec-
tive multiplex assay of the ten most frequent BRCA1 and
BRCA2  mutations in Spain, for the initial screening of
Spanish and Spanish ancestry population's breast/ovarian
cancer families.
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